HLB announced on the 21st that
the targeted anti-cancer drug Rivoceranib showed superior mPFS compared to the
control group in the first phase of Non-Small Cell Lung Cancer (NSCLC)
treatment Phase 3 clinical trials. The results of the trial that were conducted
by Zhongshan University in Guangzhou, China, were announced at the 2020 ESMO.
Earlier this year, Hengrui Medicine received clinical 3 phase approval for
NSCLC for the combination therapy of both Rivoceranib+Gefitinib and
Rivoceranib+Camrelizumab.
The abstract of the paper are as follows:
LBA50 - ACTIVE: Apatinib plus gefitinib
versus placebo plus gefitinib as first-line treatment for advanced epidermal
growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): A
multicentered, randomized, double-blind, placebo-controlled phase III trial
(CTONG1706)
Presentation Number
LBA50
Lecture Time
15:09 - 15:21
Speakers
Li Zhang (Guangzhou, China)
Abstract
Background
Blocking vascular endothelial growth factor
receptor (VEGFR) pathway can enhance the efficacy of EGFR-TKI in EGFRm NSCLC.
ACTIVE is the first phase III study evaluating apatinib, an oral small molecule
VEGFR2-TKI, or placebo plus gefitinib as first-line therapy in patients (pts)
with EGFRm NSCLC.
Methods
Treatment-naïve pts with classic EGFR
mutation (ex19del or L858R) were randomized (1:1) to receive once-daily oral
apatinib 500 mg plus gefitinib 250 mg (AG arm) or placebo plus gefitinib 250 mg
(G arm). Stratification factors: EGFR mutation type (ex19del, L858R), sex, and
performance status (0, 1). The primary endpoint was PFS (RECIST 1.1) assessed
by blinded independent radiology review committee (IRRC). Secondary endpoints:
PFS by investigator (INV), OS, ORR, DCR, DOR, TTPD, QoL and safety.
Next-generation sequencing (NGS) was used to analyze baseline and
post-progression samples for exploring efficacy predictors and acquired
resistance.
Results
313 pts were enrolled (AG arm, n=157; G
arm, n=156). Median follow-up was 15.8 months (IQR 12.6, 20.4). Median PFS by
IRCC was 13.7 versus 10.2 months in AG and G arms (HR = 0.71, 95% CI 0.54-0.95;
p = 0.0189). Prolonged PFS by INV (HR = 0.71, 95% CI 0.53-0.95) was observed.
OS data are immature at cutoff (29.4% events). ORR was 77.1% and 73.7% in AG
and G arms (p = 0.5572). Pts with ex19del had better HR than L858R (HR = 0.67,
0.45-0.99; 0.72, 0.48-1.09). NGS results of baseline samples showed a
marginally significant improved PFS in TP53-mutant disease. Pts with TP53 exon
8 mutation significantly benefited from dual blockade (HR = 0.24, 0.06-0.91).
Grade 3-4 adverse events (AEs) of the two arms were similar, except increased
risk of hypertension and proteinuria (46.5%; 17.8%) in AG arm. No AEs beyond
expectation were reported. Other endpoints and NGS results for resistance will
be presented onsite.
Conclusions
Apatinib plus gefitinib as first-line
therapy demonstrated superior PFS. TP53 exon 8 mutation status could serve as
an efficacy predictor. Safety profiles were consistent with that of the
individual drugs and acceptable.
Clinical trial identification
NCT02824458.
Legal entity responsible for the study
Sun Yat-sen University Cancer Center.
Funding
The 5010 Clinical Research Foundation of
Sun Yat-sen University; Jiangsu Hengrui Medicine Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.